Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06395350
Other study ID # PR 2019-337
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 4, 2019
Est. completion date September 20, 2019

Study information

Verified date October 2019
Source Spire, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This usability validation testing protocol outlines the methods being used to demonstrate and gather evidence that the current design and user experience of the Spire Remote Patient Monitor are safe and effective for use by the people who are representative of the intended users under expected use conditions. This summative testing is the culmination of several preliminary analyses including a formative usability evaluation via Cognitive Expert Review Panel and is intended to assess the effectiveness of control measures put in place to reduce/eliminate use-related hazards or potential use errors.


Description:

The summative testing will address user interactions with all components of the Spire Remote Patient Monitor related to tasks associated with the user group, including the Medical Health Tags, SpireHealth Mobile Application and Healthcare Provider Dashboard. This protocol specifies the required testing methods and associated acceptance criteria, as well as other information necessary to collect that evidence. This human factors summative test is aimed to uncover the following: - Determine if the final system design is safe and effective for use by the intended users in the intended use environment - Investigation of any use errors related to risk observed - To identify any potential new use errors relating to risk Background Empirical activities in the form of a Cognitive Expert Review Panel was conducted to evaluate design iterations on critical tasks prior to summative testing. The results of these activities were used to improve UI design and inform analytical analyses such as task analysis, PCA analysis and use error analysis (DOC-75057 Use Error Analysis) This validation includes all Spire Remote Patient Monitor system interfaces associated with the primary consumer user groups. The Spire Remote Patient Monitor that are the subject of this validation need to be supported by the following devices: - SpireHealth Mobile Application running on a compatible smart phone (Apple iPhone or Android phone) - Medical Health Tag device - Spire Healthcare Provider Dashboard running in a browser on a personal computer Prior to this summative testing there will be no training activities. Support and help are embedded within the app experience and Instructions for Use (IFU). Seventeen (17) users will be recruited who comprise the single Spire Remote Patient Monitor user group: adults for whom remote monitoring has been indicated by a health professional. At least 15 usable data points will be collected. This sample size is based on the recommendation number of participants in IEC 62366: 2015, Part 1 and Part 2. The increased participant size is also to allow for cancellations and other test anomalies (e.g., equipment failures). Session Description: 60 minutes, one-on-one session Session Activities 1. Introduction and background questions: 5 minutes 2. Device in-use evaluation (observations and questions): 45 minutes 3. The final follow-up and closing: 10 minutes The Facilitator's Script is allows for consistent interaction between the facilitators and the participants. As per the facilitator's discretion, any deviation to the exact script will be based on real-time responses to the session flow and responding the individual interaction. The script will have a list of questions specific to each scenario designed to help the facilitator/observer refine the information, to improve consistency of reporting, and assist the facilitator/observer in root cause analysis.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date September 20, 2019
Est. primary completion date September 20, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Must indicate that they are interested in using a smartphone and/or wearable fitness device for tracking their health - High school degree or equivalent (e.g., GED) or less - at least 2 - Some college but no degree or associate degree - at least 4 - Age 22-49 - at least 5 - Age 50-65 - at least 5 - Age Over 65 - at least 2 - Near even split of men and women - Almost never limited by my physical condition - Rarely limited by my physical condition - Occasionally limited by my physical condition - Often limited by my physical condition - Almost always limited by my physical condition - Users with iPhone experience - Smart Phone Savviness - No more than 7 users who own use a wearable fitness device - Wearable Fitness Device savviness Exclusion Criteria: - Participant currently works in tech industry - Participant or a member of his/her household currently works for any company that develops, manufactures, or sells smartphones or smart wearable fitness devices - Participant has participated in market or user research related to a medical device within the last 6 months and has participated in more than 2 in the last 3 years - Participants are trained clinicians or healthcare providers

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Spire Health Monitor
Use of Health Monitor is Assessed

Locations

Country Name City State
United States Arthur Cabrera, MD. Louisville Colorado

Sponsors (2)

Lead Sponsor Collaborator
Spire, Inc. Clinimark, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the participant's ability to perform essential tasks related to handling of device measured by Pass/Fail Observational techniques will be used to assess the participant's ability to easily use various features on the device and discover whether user errors occur. 60 minutes
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1